Raymond James & Associates’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-232
| Closed | -$16K | – | 4102 |
|
|
2021
Q3 | $16K | Buy |
232
+66
| +40% | +$4.55K | ﹤0.01% | 3907 |
|
|
2021
Q2 | $13K | Buy |
+166
| New | +$13K | ﹤0.01% | 3890 |
|
|
2019
Q4 | – | Sell |
-916
| Closed | -$45K | – | 3630 |
|
|
2019
Q3 | $45K | Buy |
916
+235
| +35% | +$11.5K | ﹤0.01% | 3431 |
|
|
2019
Q2 | $62K | Buy |
681
+22
| +3% | +$2K | ﹤0.01% | 3426 |
|
|
2019
Q1 | $97K | Sell |
659
-50
| -7% | -$7.36K | ﹤0.01% | 3358 |
|
|
2018
Q4 | $112K | Buy |
709
+256
| +57% | +$40.4K | ﹤0.01% | 3267 |
|
|
2018
Q3 | $111K | Buy |
+453
| New | +$111K | ﹤0.01% | 3381 |
|
|
2018
Q1 | – | Sell |
-154
| Closed | -$47K | – | 3457 |
|
|
2017
Q4 | $47K | Sell |
154
-76
| -33% | -$23.2K | ﹤0.01% | 3223 |
|
|
2017
Q3 | $84K | Buy |
230
+76
| +49% | +$27.8K | ﹤0.01% | 3156 |
|
|
2017
Q2 | $56K | Sell |
154
-2,445
| -94% | -$889K | ﹤0.01% | 3114 |
|
|
2017
Q1 | $773K | Buy |
2,599
+158
| +6% | +$47K | ﹤0.01% | 2120 |
|
|
2016
Q4 | $538K | Buy |
2,441
+889
| +57% | +$196K | ﹤0.01% | 2286 |
|
|
2016
Q3 | $373K | Buy |
+1,552
| New | +$373K | ﹤0.01% | 2469 |
|
|
2016
Q2 | – | Sell |
-586
| Closed | -$252K | – | 2966 |
|
|
2016
Q1 | $252K | Sell |
586
-196
| -25% | -$84.3K | ﹤0.01% | 2441 |
|
|
2015
Q4 | $296K | Buy |
+782
| New | +$296K | ﹤0.01% | 2194 |
|
|
2015
Q2 | – | Sell |
-740
| Closed | -$204K | – | 2448 |
|
|
2015
Q1 | $204K | Buy |
+740
| New | +$204K | ﹤0.01% | 2310 |
|